You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Colorcon
Johnson and Johnson
Dow
McKesson

Last Updated: March 7, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for N,N-Dimethyltryptamine

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug N,N-Dimethyltryptamine?

N,N-Dimethyltryptamine is an investigational drug.

There have been 6 clinical trials for N,N-Dimethyltryptamine. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2020.

The most common disease conditions in clinical trials are Depression, Alcoholism, and Alcohol Drinking. The leading clinical trial sponsors are Heffter Research Institute, Johns Hopkins University, and Beckley Foundation.

There are one hundred and fifty US patents protecting this investigational drug and eight hundred and seventy-five international patents.

Recent Clinical Trials for N,N-Dimethyltryptamine
TitleSponsorPhase
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use DisorderJohns Hopkins UniversityPhase 2
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS SurvivorsHeffter Research InstitutePhase 1
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS SurvivorsRiver Styx FoundationPhase 1

See all N,N-Dimethyltryptamine clinical trials

Clinical Trial Summary for N,N-Dimethyltryptamine

Top disease conditions for N,N-Dimethyltryptamine
Top clinical trial sponsors for N,N-Dimethyltryptamine

See all N,N-Dimethyltryptamine clinical trials

US Patents for N,N-Dimethyltryptamine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
N,N-Dimethyltryptamine   Start Trial Methods of improving behavioral therapies Emory University (Atlanta, GA)   Start Trial
N,N-Dimethyltryptamine   Start Trial Complex and structurally diverse compounds The Board of Trustees of the University of Illinois (Urbana, IL)   Start Trial
N,N-Dimethyltryptamine   Start Trial Factor XIa inhibitors Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
N,N-Dimethyltryptamine   Start Trial Pharmaceutical compositions resistant to abuse EGALET LTD. (London, GB)   Start Trial
N,N-Dimethyltryptamine   Start Trial Formulations of histone deacetylase inhibitor and uses thereof Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
N,N-Dimethyltryptamine   Start Trial Methods, devices and systems for pulmonary delivery of active agents Syqe Medical Ltd. (Tel-Aviv, IL)   Start Trial
N,N-Dimethyltryptamine   Start Trial Abuse-deterrent controlled release formulations Patheon Softgels Inc. (High Point, NC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for N,N-Dimethyltryptamine

Drugname Country Document Number Estimated Expiration Related US Patent
N,N-Dimethyltryptamine World Intellectual Property Organization (WIPO) WO2013142873 2032-03-23   Start Trial
N,N-Dimethyltryptamine European Patent Office EP3134408 2034-04-22   Start Trial
N,N-Dimethyltryptamine World Intellectual Property Organization (WIPO) WO2015164308 2034-04-22   Start Trial
N,N-Dimethyltryptamine Australia AU2010211376 2029-02-06   Start Trial
N,N-Dimethyltryptamine Australia AU2013257533 2029-02-06   Start Trial
N,N-Dimethyltryptamine Canada CA2751627 2029-02-06   Start Trial
N,N-Dimethyltryptamine Denmark DK2393487 2029-02-06   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Colorcon
Johnson and Johnson
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.